Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Yin, Li ^a,b   Zhang, Xin Tian ^a   Bian, Xiu Wu ^b   Guo, Yu Ming ^a   Wang, Zhao Yi ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BROUSSOFLAVONOL B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA36; FLAVONOL; LAPATINIB; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN;

ARTICLE; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG POTENTIATION; MCF 7 CELL LINE; PROTEIN EXPRESSION; BREAST NEOPLASMS; DOWN REGULATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84929941313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107369     Document Type: Article

References (49)

1. Macgregor JI, Jordan VG (1998) Basic guide to the mechanisms of antiestrogens action. Phamacological Review 50: 151-196.
2. Clarke R, Leonessa F, Welch JN, Skaar TC (2001) Cellular and molecular pharmacology of antiestrogens action and resistance. Phamacological Review 53: 25-71.
3. Clarke RB, Liu MC, Bouker KB, Gu ZP, Lee RY, et al. (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339.
4. Normanno N, Di Maio M, De Maio E, De Luca A, Matteis AD, et al. (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine-Related Cancer 12: 721-747.
5. Normanno N, Di Maio M, De Maio E, De Luca A, Matteis AD, et al. (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine-Related Cancer 4: 721-747.
6. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Ann Rev. Med 62: 233-247.
7. Ravdin PM, Green S, Albain KS, Boucher V, Ingle J, et al. (1998) Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone (ABSTRACT). Program/Proc. Am. Soc. Clin. Oncol 17: 97a.
8. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, et al. (1991) Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296-3303.
9. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, et al. (2000) HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J. Clin. Oncol 18: 3471-3479.
10. Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, et al. (1994) ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137-144.
11. Carlomango C, Perrone F, Gallo C, De Laurentiis M, Lauria R, et al. (1996) c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in earlystage breast cancer without axillary lymph node metastases. J. Clin. Oncol 14: 2702-2708.
12. Leitzel K, Teramoto Y, Konrad K, Chinchilli V M, Volas G, et al. (1995) Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol 13: 1129-1135.
13. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, et al. (1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER- 2/c-neu protein. J. Clin. Oncol 15: 2518-2525.
14. Bianco AR, De Laurentis M, Carlomango C, Lauria R, Petrella G, et al. (1998) 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-B2 expression and tamoxifen efficacy (ABSTRACT). Program/Proc. Am. Soc. Clin. Oncol 17: 97a.
15. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, et al. (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin Cancer Res 4: 7-12.
16. Witters LM, Kumar R, Chinchilli VM, Lipton A (1997) Enhanced antiproliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res. Treat., 42: 0167-6806.
17. Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, et al. (2000) Anti- Her2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br. J. Cancer 82: 46-52.
18. Kurokawa H, Lenferink AEG, Simpson JF, Pisacane PI, Sliwkowski MX, et al. (2000) Inhibition of HER/neu (erB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887-5894.
19. Chu I, Blackwell K, Chen S, Slingerland J (2005) The dual ErbB1 and ErbB2 inhibitor, Lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65: 18-25.
20. Wang ZY, Zhang XT, Shen P, Loggie BW, Chang YC, et al. (2005) Identification, cloning and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-A. Biochem. Biophy. Res. Commun 336: 1023-1027.
21. Wang ZY, Zhang XT, Shen P, Loggie BW, Chang YC, et al. (2006) A variant of estrogen receptor-A, hER-α36: transduction of estrogen and anti-estrogen dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. U.S.A 103: 9063-9068.
22. Zou Y, Ding L, Coleman M, Wang ZY (2009) Estrogen receptor-Alpha (ER-α) suppresses expression of its variant ER-α36. FESEB Letters 583: 1368-1374.
23. Shi L, Dong B, Li ZW, Lu YW, Ouyang T, et al. (2009) Expression of ER-α36, a novel variant of estrogen receptor-A, and resistance to tamoxifen treatment in breast cancer. J. Clinical Oncology 27: 3423-3429.
24. Zhang XT, Ding L, Kang LG, Wang ZY (2012) Estrogen receptor-Alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLos ONE 7: e30174.
25. Lin SL, Yan LY, Zhang XT, Yuan J, Li M, et al. (2010) ER-α36, a variant of ER-α, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLos ONE 5: e9013.
26. Zhang XT, Wang ZY (2013) Estrogen receptor-A variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity. Endocrinology 154: 1990-1998.
27. Li GL, Zhang J, Jin KT, He KF, Zheng Y, et al. (2013) Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Mol Oncol 7: 611-624.
28. Zhang XT, Kang LG, Ding L, Vranic S, Gatalic Z, et al. (2011) A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 30: 770-780.
29. Kang LG, Guo YM, Zhang XT, Meng J, Wang ZY (2011) A positive crossregulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology 127: 262-268.
30. Zhang XT, Deng H, Wang ZY (2014) Estrogen activation of the mitogenactivated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology 143: 434-443.
31. Massarweh S, Osborne CK, Creighton CJ, Qin LF, Tsimelzon A, et al. (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer res 68: 826-833.
32. Guo MX, Wang ML, Zhang XY, Deng H, Wang ZY (2013) Broussoflavonol B restricts growth of ER-negative breast cancer stem-like cells''. AntiCancer Research 1873-1880.
33. Guo MX, Wang ML, Zhang XT, Deng H, Wang ZY (2013) A novel anticancer agent Broussoflavonol B Downregulates ER-α36 expression and inhibits growth of ER-negative breast cancer MDA-MB-231 cells. European Journal of Pharmacology 714: 56-64.
34. Deng H, Zhang XT, Wang ML, Zheng HY, Liu LJ, et al. (2014) ER-α36 mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells. PLos ONE 9: e88034.
35. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 Is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 5: 555-567.
36. Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, et al. (2009) Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 100: 1062-1068.
37. Leary AF, Drury S, Detre S, Pancholi S, Pancholi S, et al. (2010) Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin. Cancer Res 16: 1486-1497.
38. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, et al. (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogen 28: 803-814.
39. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 96: 926-935.
40. Kang LG, Wang ZY (2010) Growth inhibition of ER-positive breast cancer cells by Phenethyl Isothiocyanate is associated with downregulation of ER-α36, a variant of estrogen receptor-Alpha. J. Cellular and Molecular Medicine 14: 1485-1493.
41. Oliveira LR, Jeffrey SS, Ribeiro-Silva A (2010) Stem cells in human breast cancer. Histol. Histopathol. 2010, 25: 371-385.
42. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, et al. (2010) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270.
43. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 302-313.
44. O'Brien CS, Howell SJ, Farnie G, Clarke RB (2009) Resistance to endocrine therapy: are breast cancer stem cells culprits. J. Mammary Gland Biol Neoplasia 14: 45-54.
45. Piva M, Domenici G, O Iriondo O, Rábano M, Simões BM et al. (2013) Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med 5: 1-14.
46. Korkaya H, Paulson A, Iovino F, Wicha MS (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-6130.
47. Korkaya H, Paulson A, Charfe-Jauffret E, Ginestier C, Brown M, et al. (2009) Regulation of mammary stem/progenitor cells by PTEN/Akt/b-catenin signaling. PLoS Biology 7: e1000121.
48. Han JS, Crowe DL (2009) Tumor initiating cancer stem cells from human breast cancer cell lines. Int J Oncol 34: 1449-1453.
49. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, et al. (2007) WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. USA 104: 618-623.